Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer

Breast Cancer Research and Treatment

Volumn 97, Issue 2, 2006, Pages 199-203

  Tokunaga, Eriko ^a   Oki, Eiji ^a   Nishida, Kojiro ^a   Koga, Tadashi ^a   Yoshida, Rintaro ^a   Ikeda, Keisuke ^a   Kojima, Aya ^a   Egashira, Akinori ^a   Morita, Masaru ^a   Kakeji, Yoshihiro ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Aberrant hypermethylation; Breast cancer; CFHR; Methylation specific PCR; Taxane

Indexed keywords

CHECKPOINT WITH FORKHEAD ASSOCIATED AND RING FINGER PROTEIN; GENE PRODUCT; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL SURVIVAL; CHFR GENE; COLON CANCER; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; DRUG MECHANISM; DRUG SENSITIVITY; ESOPHAGUS CANCER; GENE ACTIVATION; GENE CONTROL; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; METAPHASE; MICROTUBULE ASSEMBLY; MITOSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STOMACH CANCER; TUMOR CELL;

BREAST NEOPLASMS; CELL CYCLE PROTEINS; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; HUMANS; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS);

EID: 33646568092     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9112-9     Document Type: Article

References (29)

1. Nowak AK, Wilcken NR, Stockler MR, Hamilton A, Ghersi D: Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 5: 372-380, 2004
2. Crown J, O'Leary M, Ooi WS: Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9(Suppl 2): 24-32, 2004
3. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G, Bhalla K: High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8: 1960-1969, 1994
4. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, Bhalla K: Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 11: 253-257, 1997
5. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS: Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118-17125, 1997
6. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, Hung MC: Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 2: 581-591, 1998
7. Gelmon K: The taxoids: paclitaxel and docetaxel. Lancet 344: 1267-1272, 1994
8. Donaldson KL, Goolsby GL, Kiener PA, Wahl AF: Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 5: 1041-1050, 1994
9. Sudo T, Nitta M, Saya H, Ueno NT: Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64: 2502-2508, 2004
10. Cahill DP, da Costa LT, Carson-Walter EB, Kinzler KW, Vogelstein B, Lengauer C: Characterization of MAD2B and other mitotic spindle checkpoint genes. Genomics 58: 181-187, 1999
11. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B: Mutations of mitotic checkpoint genes in human cancers. Nature 392: 300-303, 1998
12. Jordan MA, Wilson L: Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10: 123-130, 1998
13. Shichiri M, Yoshinaga K, Hisatomi H, Sugihara K, Hirata Y: Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res 62: 13-17, 2002
14. Scolnick DM, Halazonetis TD: CHFR defines a mitotic stress checkpoint that delays entry into metaphase. Nature 406: 430-435, 2000
15. Bertholon J, Wang Q, Falette N, Verny C, Auclair J, Chassot C, Navarro C, Saurin JC, Puisieux A: CHFR inactivation is not associated to chromosomal instability in colon cancers. Oncogene 22: 8956-8960, 2003
16. Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, Halazonetis TD, El-Deiry WS: Frequent hypermethylation of the 5′ CpG island of the mitotic stress checkpoint gene CHFR in colorectal and non-small cell lung cancer. Carcinogenesis 24: 47-51, 2003
17. Mariatos G, Bothos J, Zacharatos P, Summers MK, Scolnick DM, Kittas C, Halazonetis TD, Gorgoulis VG: Inactivating mutations targeting the CHFR mitotic checkpoint gene in human lung cancer. Cancer Res 63: 7185-7189, 2003
18. Mizuno K, Osada H, Konishi H, Tatematsu Y, Yatabe Y, Mitsudomi T, Fujii Y, Takahashi T: Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene 21: 2328-2333, 2002
19. Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, Kikuchi T, Mita H, Yamashita T, Kojima T, Kusano M, Fujita M, Hosokawa M, Endo T, Tokino T, Imai K: Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63: 8606-8613, 2003
20. Shibata Y, Haruki N, Kuwabara Y, Ishiguro H, Shinoda N, Sato A, Kimura M, Koyama H, Toyama T, Nishiwaki T, Kudo J, Terashita Y, Konishi S, Sugiura H, Fujii Y: CHFR expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis 23: 1695-1699, 2002
21. Takahashi T, Shivapurkar N, Riquelme E, Shigematsu H, Reddy J, Suzuki M, Miyajima K, Zhou X, Bekele BN, Gazdar AF, Wistuba II: Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis. Clin Cancer Res 10: 6126-6133, 2004
22. Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H, Mita H, Tanaka N, Itoh F, Issa JP, Jair KW, Schuebel KE, Imai K, Tokino T: Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci U S A 100: 7818-7823, 2003
23. Japanese Breast Cancer Society: General Rules for Clinical and Pathological Recording of Breast Cancer. (14 th edn). Tokyo, Kanehara, 2001
24. Tokunaga E, Oki E, Oda S, Kataoka A, Kitamura K, Ohno S, Maehara Y, Sugimachi K: Frequency of microsatellite instability in breast cancer determined by high-resolution fluorescent microsatellite analysis. Oncology 59: 44-49, 2000
25. Cheung HW, Ching YP, Nicholls JM, Ling MT, Wong YC, Hui N, Cheung A, Tsao SW, Wang Q, Yeun PW, Lo KW, Jin DY, Wang X: Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. Mol Carcinog 43: 237-245, 2005
26. Erson AE, Petty EM: CHFR-associated early G2/M checkpoint defects in breast cancer cells. Mol Carcinog 39: 26-33, 2004
27. Brandes JC, van Engeland M, Wouters KA, Weijenberg MP, Herman JG: CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis 26: 1152-1156, 2005
28. Honda T, Tamura G, Waki T, Kawata S, Nishizuka S, Motoyama T: Promoter hypermethylation of the CHFR gene in neoplastic and non-neoplastic gastric epithelia. Br J Cancer 90: 2013-2016, 2004
29. Kang HC, Kim IJ, Park JH, Shin Y, Park HW, Ku JL, Yang HK, Lee KU, Choe KJ, Park JG: Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers. Oncol Rep 12: 129-133, 2004